

**Oklahoma Health Care Authority
Drug Utilization Review Board**

(DUR Board)

Meeting – November 13, 2013 @ 6:00 p.m.

Oklahoma Health Care Authority
2401 N.W. 23rd Street, Suite 1-A
Oklahoma City, Oklahoma 73107
Ponca Room (North Entrance)

AGENDA

Discussion and Action on the Following Items:

Items to be presented by Dr. Muchmore, Chairman:

1. Call To Order

- A. Roll Call – Dr. Cothran

Items to be presented by Dr. Muchmore, Chairman:

2. Public Comment Forum

- A. Acknowledgment of Speakers and Agenda Items

Items to be presented by Dr. Muchmore, Chairman:

3. Action Item – Approval of DUR Board Meeting Minutes – See Appendix A

- A. September 11, 2013 DUR Minutes – Vote
- B. September 11, 2013 DUR Recommendation Memorandum
- C. October 9, 2013 DUR Recommendation Memorandum

Items to be presented by Dr. Cothran, Dr. Muchmore, Chairman:

4. Action Item – Vote on 2014 Meeting Dates – See Appendix B

Items to be presented by Dr. Holderread, Dr. Muchmore, Chairman:

5. Action Item – Update on DUR / Medication Coverage Authorization Unit / Safety Alerts and 30 Day Notice to Prior Authorize Ketoconazole Oral Tablets – See Appendix C

- A. Medication Coverage Activity for October 2013
- B. Pharmacy Help Desk Activity for October 2013
- C. Valproate Product Update
- D. Ketoconazole Safety Communication and 30 Day Notice to Prior Authorize Ketoconazole Oral Tablets
- E. Update on Safety Alerts

Items to be presented by Dr. Le, Dr. Muchmore, Chairman

6. Annual Review of Botulinum Toxins – See Appendix D

- A. Current Prior Authorization Criteria
- B. Utilization Review
- C. Prior Authorization Review
- D. Market News and Updates
- E. COP Recommendations

Items to be presented by Dr. Holderread, Dr. Muchmore, Chairman

7. Annual Review of Prenatal Vitamins – See Appendix E

- A. Current Prior Authorization Criteria
- B. Utilization Review
- C. Prior Authorization Review
- D. COP Recommendations
- E. Utilization Details

Items to be presented by Dr. Holderread, Dr. Muchmore, Chairman

8. Annual Review of Antihypertensive Medications and 30 Day Notice to Prior Authorize Epaned™ – See Appendix F

- A. Current Prior Authorization Criteria
- B. Utilization Review
- C. Prior Authorization Review
- D. Market News and Updates
- E. Product Summary
- F. COP Recommendations
- G. Utilization Details
- H. Product Details

Items to be presented by Dr. Teel, Dr. Muchmore, Chairman

9. Annual Review of Nasal Allergy Medications and 30 Day Notice to Prior Authorize Zetonna® – See Appendix G

- A. Current Prior Authorization Criteria
- B. Utilization Review
- C. Prior Authorization Review
- D. Market News and Updates
- E. COP Recommendation
- F. Utilization
- G. Product Details

Items to be presented by Dr. Adams, Dr. Muchmore, Chairman

10. Annual Review of Glaucoma Medications and 30 Day Notice to Prior Authorize Simbrinza™ and Rescula® – See Appendix H

- A. Current Prior Authorization Criteria
- B. Utilization Review
- C. Prior Authorization Review
- D. Market News and Updates
- E. COP Recommendation
- F. Utilization Details
- G. Product Details

Items to be presented by Dr. Adams, Dr. Muchmore, Chairman

11. Annual Review of Pediculicides and 30 Day Notice to Prior Authorize Sklice® – See Appendix I

- A. Current Prior Authorization Criteria
- B. Utilization Review
- C. Prior Authorization Review
- D. Market News and Updates
- E. COP Recommendations